Arnais, Raisyl .
HRN: 23-64-73 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/02/2023
CO-AMOXICLAV 625MG (TAB)
09/02/2023
09/08/2023
PO
625mg
BID
PROM; S/p RMLE + Repair
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes